$2.24
-0.215[-8.76%]
At close: Apr 23
$2.24
0[0.00%]
After Hours: 4:42PM EDT
OncoCyte
(NASDAQ:OCX)OncoCyte Stock (NASDAQ:OCX), Analyst Ratings, Price Targets, Predictions
OncoCyte Corp has a consensus price target of $2.79, established from looking at the 26 latest analyst ratings. The last 3 analyst ratings were released from Needham, Stephens & Co., and Benchmark on April 24, 2024, April 17, 2024, and April 15, 2024. With an average price target of $4.42 between Needham, Stephens & Co., and Benchmark, there's an implied 97.17% upside for OncoCyte Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
Stephens & Co.
Benchmark
Piper Sandler
Lake Street
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for OncoCyte
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/24/2024 | OCX | Buy Now | OncoCyte | $2.24 | 89.73% | Needham | Mike Matson | $3.6 → $4.25 | Maintains | Buy | Get Alert |
| 04/17/2024 | OCX | Buy Now | OncoCyte | $2.24 | 78.57% | Stephens & Co. | Mason Carrico | → $4 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 04/15/2024 | OCX | Buy Now | OncoCyte | $2.24 | 123.21% | Benchmark | Bruce Jackson | → $5 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 11/13/2023 | OCX | Buy Now | OncoCyte | $2.24 | 33.93% | Piper Sandler | David Westenberg | $3.5 → $3 | Maintains | Neutral | Get Alert |
| 11/09/2023 | OCX | Buy Now | OncoCyte | $2.24 | 60.71% | Needham | Mike Matson | $4.25 → $3.6 | Maintains | Buy | Get Alert |
| 08/24/2023 | OCX | Buy Now | OncoCyte | $2.24 | 123.21% | Benchmark | Bruce Jackson | $9 → $5 | Maintains | Speculative Buy | Get Alert |
| 08/15/2023 | OCX | Buy Now | OncoCyte | $2.24 | 56.25% | Piper Sandler | David Westenberg | $6 → $3.5 | Maintains | Neutral | Get Alert |
| 08/10/2023 | OCX | Buy Now | OncoCyte | $2.24 | 89.73% | Needham | Mike Matson | $9 → $4.25 | Maintains | Buy | Get Alert |
| 04/04/2023 | OCX | Buy Now | OncoCyte | $2.24 | -79.91% | Needham | Mike Matson | $28 → $9 | Maintains | Buy | Get Alert |
| 12/01/2022 | OCX | Buy Now | OncoCyte | $2.24 | -77.68% | Lake Street | Thomas Flaten | $60 → $10 | Downgrade | Buy → Hold | Get Alert |
| 11/18/2022 | OCX | Buy Now | OncoCyte | $2.24 | -77.68% | Piper Sandler | David Westenberg | $20 → $10 | Downgrade | Overweight → Neutral | Get Alert |
| 11/14/2022 | OCX | Buy Now | OncoCyte | $2.24 | -55.36% | Piper Sandler | David Westenberg | $30 → $20 | Maintains | Overweight | Get Alert |
| 11/11/2022 | OCX | Buy Now | OncoCyte | $2.24 | -37.5% | Needham | Mike Matson | $42 → $28 | Maintains | Buy | Get Alert |
| 08/17/2022 | OCX | Buy Now | OncoCyte | $2.24 | -33.04% | Piper Sandler | David Westenberg | $28 → $30 | Maintains | Overweight | Get Alert |
| 08/11/2022 | OCX | Buy Now | OncoCyte | $2.24 | 33.93% | Lake Street | Thomas Flaten | $120 → $60 | Maintains | Buy | Get Alert |
| 08/11/2022 | OCX | Buy Now | OncoCyte | $2.24 | -6.25% | Needham | Mike Matson | $45 → $42 | Maintains | Buy | Get Alert |
| 05/24/2022 | OCX | Buy Now | OncoCyte | $2.24 | — | Stephens & Co. | Mason Carrico | — | Downgrade | Overweight → Equal-Weight | Get Alert |
| 05/16/2022 | OCX | Buy Now | OncoCyte | $2.24 | -37.5% | Piper Sandler | David Westenberg | $36 → $28 | Maintains | Overweight | Get Alert |
| 05/12/2022 | OCX | Buy Now | OncoCyte | $2.24 | 0.45% | Needham | Mike Matson | $80 → $45 | Maintains | Buy | Get Alert |
FAQ
What is the target price for OncoCyte (OCX)?
The latest price target for OncoCyte (NASDAQ: OCX) was reported by Needham on April 24, 2024. The analyst firm set a price target for $4.25 expecting OCX to rise to within 12 months (a possible 89.73% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for OncoCyte (OCX)?
The latest analyst rating for OncoCyte (NASDAQ: OCX) was provided by Needham, and OncoCyte maintained their buy rating.
When was the last upgrade for OncoCyte (OCX)?
There is no last upgrade for OncoCyte.
When was the last downgrade for OncoCyte (OCX)?
The last downgrade for OncoCyte Corp happened on December 1, 2022 when Lake Street changed their price target from $3 to $0.5 for OncoCyte Corp.
When is the next analyst rating going to be posted or updated for OncoCyte (OCX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of OncoCyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for OncoCyte was filed on April 24, 2024 so you should expect the next rating to be made available sometime around April 24, 2025.
Is the Analyst Rating OncoCyte (OCX) correct?
While ratings are subjective and will change, the latest OncoCyte (OCX) rating was a maintained with a price target of $3.60 to $4.25. The current price OncoCyte (OCX) is trading at is $2.24, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.